{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Stratified log-rank test was used to compare overall survival between the two arms.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.48","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.2","upperLimit":"65.2","value":"64.0"},{"comment":"Median overall survival was not reached in Arm B.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to death or date of last known alive. The OS results are based on data as of April 2014.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.\n\nbortezomib: Given IV\n\nlenalidomide: Given PO\n\ndexamethasone: Given PO","id":"OG000","title":"Arm A (VRD)"},{"description":"Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.\n\nbortezomib: Given IV\n\ndexamethasone: Given PO","id":"OG001","title":"Arm B (VD)"}],"paramType":"MEDIAN","populationDescription":"All randomized patients","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, every 12 months if patient is 6-10 years from study entry, up to 10 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}